Self-administered injectable contraceptives have been available in the United States for more than two decades, yet a new ...

At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, ...

A new contraceptive option provides a possible answer to an age-old question in family planning: how to address barriers that make it difficult for women to keep using contraception consistently.

The injectable contraceptive depot-medroxyprogesterone acetate (DMPA) appears to increase a woman’s risk of acquiring the sexually transmitted infections chlamydia and gonorrhea by approximately three ...

Expert Rev of Obstet Gynecol. 2010;5(6):673-686. Each year worldwide, over 380,000 women die from pregnancy and pregnancy-related causes. If contraception were made available to unprotected women, ...

DMPA SC does not protect against HIV infection (AIDS) or other sexually transmitted diseases. Injection site reactions such as injection site pain, injection site tenderness, injection site nodules, ...

Depot-medroxyprogesterone acetate is a commonly used injectable contraceptive that has been associated with an increased risk of HIV acquisition. This study compares effects of ...

"This is an exciting milestone for women in the United Kingdom, and, potentially, in countries around the world, who might prefer this method of contraception and mode of administration." Pfizer Inc.